Flexion Therapeutics Inc (NASDAQ:FLXN) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 1,991 call options on the company. This represents an increase of 1,911% compared to the typical volume of 99 call options.
In related news, insider Michael D. Clayman acquired 4,046 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average cost of $12.36 per share, for a total transaction of $50,008.56. Following the purchase, the insider now directly owns 70,856 shares of the company’s stock, valued at approximately $875,780.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.59% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in Flexion Therapeutics by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 152,355 shares of the specialty pharmaceutical company’s stock valued at $2,851,000 after purchasing an additional 9,460 shares during the period. Vanguard Group Inc grew its holdings in Flexion Therapeutics by 1.1% in the third quarter. Vanguard Group Inc now owns 1,619,112 shares of the specialty pharmaceutical company’s stock valued at $30,294,000 after purchasing an additional 18,323 shares during the period. Capital International Investors acquired a new stake in Flexion Therapeutics in the third quarter valued at approximately $12,162,000. Virtu Financial LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter valued at approximately $240,000. Finally, Next Capital Management LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter valued at approximately $84,000. 94.40% of the stock is currently owned by institutional investors.
Flexion Therapeutics stock traded up $0.10 during midday trading on Friday, hitting $10.77. 467,239 shares of the company were exchanged, compared to its average volume of 649,260. The company has a quick ratio of 7.58, a current ratio of 7.78 and a debt-to-equity ratio of 1.35. Flexion Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $29.10. The firm has a market cap of $409.19 million, a price-to-earnings ratio of -2.40 and a beta of 1.57.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.17. Flexion Therapeutics had a negative return on equity of 102.16% and a negative net margin of 753.24%. The company had revenue of $9.54 million for the quarter, compared to analyst estimates of $9.40 million. Equities analysts expect that Flexion Therapeutics will post -4.12 EPS for the current year.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.